您的购物车当前为空
PKI-402 是一种有效的 PI3K 和 mTOR 抑制剂,对 PI3Kα, mTOR, PI3Kβ, PI3Kδ 和 PI3Kγ 抑制的IC50 分别为 2, 3, 7, 14 和 16 nM。


为众多的药物研发团队赋能,
让新药发现更简单!
PKI-402 是一种有效的 PI3K 和 mTOR 抑制剂,对 PI3Kα, mTOR, PI3Kβ, PI3Kδ 和 PI3Kγ 抑制的IC50 分别为 2, 3, 7, 14 和 16 nM。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 172 | 现货 | |
| 5 mg | ¥ 400 | 现货 | |
| 10 mg | ¥ 642 | 现货 | |
| 25 mg | ¥ 1,290 | 现货 | |
| 50 mg | ¥ 1,960 | 现货 | |
| 100 mg | ¥ 2,750 | 现货 |
PKI-402 相关产品
| 产品描述 | PKI-402 is a potent PI3K and mTOR inhibitor. PKI-402 inhibits PI3Kα, mTOR, PI3Kβ, PI3Kδ and PI3Kγ with IC50s of 2, 3, 7, 14 and 16 nM, respectively. |
| 靶点活性 | PI3Kβ:7 nM, PI3Kα:2 nM, PI3Kδ:14 nM, PI3Kα (E542K):3 nM, PI3Kγ:16 nM, PI3Kα (H1047R):3 nM, mTOR:3 nM |
| 体外活性 | PKI-402 causes in vitro growth inhibition of human tumor cell lines derived from a diverse set of human tumor tissues, including breast, brain (glioma), pancreas, and non-small cell lung cancer (NSCLC) tissues[1]. |
| 体内活性 | PKI-402 displays antitumor activity (i.v. route) in breast [MDA-MB-361: Her2+ and PIK3CA (E545K)], glioma (U87MG and PTEN), and NSCLC (A549; K-Ras and STK11) xenograft models. PKI-402 causes regression in the MDA-MB-361 xenograft model. |
| 分子量 | 570.65 |
| 分子式 | C29H34N10O3 |
| CAS No. | 1173204-81-3 |
| Smiles | CCn1nnc2c(nc(nc12)-c1ccc(NC(=O)Nc2ccc(cc2)C(=O)N2CCN(C)CC2)cc1)N1CCOCC1 |
| 密度 | 1.43 g/cm3 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||
| 溶解度信息 | DMSO: 5 mg/mL (8.76 mM), Sonication is recommended. | |||||||||||||||
溶液配制表 | ||||||||||||||||
DMSO
| ||||||||||||||||
评论内容